Study will evaluate investigational medication for PTSD symptoms

The trial will assess how well the investigational drug works compared with a placebo for injury-related symptoms, including sleep disruptions. This is a Phase 2 trial, made to evaluate security and effectiveness. The study is open to women and men between the ages of 18 and 65 who ve served or are serving in law enforcement, the Armed Forces or a military contractor. Study volunteers should have endured a work-related traumatic event at some point subsequent to the year 2000 and have injury-associated effects that were lingering. Volunteers will be randomly assigned to one of three groups whose members will receive differing doses of a placebo or the study drug. It is a double-blind study, meaning neither the volunteer nor the study doctor will learn which group the volunteer was delegated to. The study drug dosing interval will continue for about 12 weeks, during which time volunteers will participate in consultations and go to the study centre to get various evaluations to monitor
https://www.ptsdnews.com/study-will-evaluate-investigational-medication-for-ptsd-symptoms/84/